JPI Healthcare제이피아이헬스케어

JPI Healthcare trades near book value after a steep one-year fall, while reported half-year profit remains positive.

JPI Healthcare makes X-ray imaging components such as anti-scatter grids, sold to about 300 global medical device companies, and is expanding into digital imaging systems and AI imaging software. Trailing twelve-month revenue is ₩46.9B with operating income of ₩4.7B and net income of ₩7.0B as of H1 2026, and the share price is ₩7,820, down 61.3% over one year. The data does not explain the cause of the decline.

What stands out

• Trailing revenue of ₩46.9B is slightly below 2025 full-year revenue of ₩48.5B, and trailing operating margin is about 10%, unchanged from 2025.
• Trailing net income of ₩7.0B is well above operating income of ₩4.7B, so non-operating or other items contributed; the data does not break this down.
• Valuation metrics are low: P/E about 5.7, P/B about 0.6, dividend yield 3.2%, and a DCF base value of ₩15,407 sits above the current price, though the bear case is ₩10,957.
• Borrowings of ₩10.4B exceed cash of ₩9.5B, with liabilities at 27% of equity; trailing free cash flow is ₩3.8B.
• Filings in August 2026 cover a buyback trust contract and its termination, and foreign ownership fell from 1.2% to 0.9% over 60 days.

What to watch

• The next quarterly or annual results, and whether revenue and margins hold near the trailing levels.
• Further filings on the share buyback trust termination and any insider shareholding reports.
• The data contains no recent news headlines, so the reasons behind the share price fall are not available here.